<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03185546</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00047676</org_study_id>
    <secondary_id>1U54DA031659-01</secondary_id>
    <secondary_id>U54DA031659-06</secondary_id>
    <nct_id>NCT03185546</nct_id>
  </id_info>
  <brief_title>REN-Project 2 Cigarette and E-cigarette Nicotine Content and E-liquid Flavors</brief_title>
  <official_title>Project 2: The Impact of Cigarette Nicotine Content, E-cigarette Nicotine Content, and E-cigarette Flavoring on Smoking Behavior</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Project 2 will evaluate the impact of very low nicotine content cigarettes, e-cigarette
      nicotine content, and e-cigarette flavoring on cigarettes smoked per day, nicotine exposure,
      puff topography, discomfort/dysfunction, other health-related behaviors, nicotine/tobacco
      dependence, biomarkers of tobacco exposure, intention to quit, compensatory smoking, other
      tobacco use, cardiovascular function, and perceived risk. Project 2 will also evaluate
      differences between conditions in compliance with product use and the ability to abstain from
      cigarette smoking when provided a financial incentive for abstinence from combusted tobacco.
      This is not a treatment program for smoking.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 6, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cigarettes smoked per day</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Total cigarettes smoked per day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study cigarettes smoked per day</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Study cigarettes smoked per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fagerstrom Nicotine Dependence Scale</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Dependence Measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mercapturic Acids</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Measure of toxicant exposure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cigarette Evaluation Scale</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Measure of product subjective effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IVR Review and Timeline Followback</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Measure of smoke free days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IVR Review and Timeline Followback</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Measure of number of days using assigned vaping device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minnesota Nicotine Withdrawal Scale</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Measure of discomfort and dysfunction</description>
  </secondary_outcome>
  <other_outcome>
    <measure>IVR Review and Timeline Followback and E-liquid Accountability</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Measure of vaping device use</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of choices to smoke in preference assessment task</measure>
    <time_frame>Week 00</time_frame>
    <description>Measure of relative reinforcement</description>
  </other_outcome>
  <other_outcome>
    <measure>Purchase Task</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Measure of relative reinforcement and substitution</description>
  </other_outcome>
  <other_outcome>
    <measure>Predicted Behavior Questionnaire</measure>
    <time_frame>Week 12</time_frame>
    <description>Measure of hypothetical cigarette and vaping device use</description>
  </other_outcome>
  <other_outcome>
    <measure>IVR Review and Timeline Followback</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Measure of compliance</description>
  </other_outcome>
  <other_outcome>
    <measure>Drop-out rate</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Drop-out rate</description>
  </other_outcome>
  <other_outcome>
    <measure>Urge to Use Questionnaire</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Measure of discomfort and dysfunction</description>
  </other_outcome>
  <other_outcome>
    <measure>Center for Epidemiologic Studies Depression Scale</measure>
    <time_frame>Baseline, Weeks 04, 08, 12</time_frame>
    <description>Measure of discomfort and dysfunction</description>
  </other_outcome>
  <other_outcome>
    <measure>Breath Alcohol</measure>
    <time_frame>Baseline - Week 12</time_frame>
    <description>Alcohol use</description>
  </other_outcome>
  <other_outcome>
    <measure>Urine Drug Screen</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Drug use</description>
  </other_outcome>
  <other_outcome>
    <measure>Alcohol Use Questionnaire</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Alcohol use</description>
  </other_outcome>
  <other_outcome>
    <measure>Drug Use Questionnaire</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Drug use</description>
  </other_outcome>
  <other_outcome>
    <measure>Weight</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Weight</description>
  </other_outcome>
  <other_outcome>
    <measure>Expired Carbon Monoxide</measure>
    <time_frame>Baseline - Week 12</time_frame>
    <description>Measure of cigarette smoke exposure</description>
  </other_outcome>
  <other_outcome>
    <measure>Urinary Anatabine Biomarker</measure>
    <time_frame>Baseline -Week 12</time_frame>
    <description>Measure of cigarette exposure and compliance</description>
  </other_outcome>
  <other_outcome>
    <measure>Total Nicotine Equivalents</measure>
    <time_frame>Baseline - Week 12</time_frame>
    <description>Measure of nicotine exposure</description>
  </other_outcome>
  <other_outcome>
    <measure>Environmental and Social Influences on Tobacco Use Questionnaire</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Measure of smoking and vaping context</description>
  </other_outcome>
  <other_outcome>
    <measure>Context of Product Use Questionnaire</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Measure of smoking and vaping context</description>
  </other_outcome>
  <other_outcome>
    <measure>Puff topography</measure>
    <time_frame>Weeks 01 and 10</time_frame>
    <description>Measure of smoking and vaping topography</description>
  </other_outcome>
  <other_outcome>
    <measure>Vaping Utility Questionnaire</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Measure of product expectancy</description>
  </other_outcome>
  <other_outcome>
    <measure>Smoking and Vaping Expectancy Questionnaires</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Measure of product expectancy</description>
  </other_outcome>
  <other_outcome>
    <measure>Cigarette and Product Evaluation Scale</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Measure of product characteristics</description>
  </other_outcome>
  <other_outcome>
    <measure>Perceived Health Risk Questionnaire</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Measure of perceived personal health risk</description>
  </other_outcome>
  <other_outcome>
    <measure>Penn State Smoking Dependence Questionnaire</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Dependence Measure (smoking and vaping)</description>
  </other_outcome>
  <other_outcome>
    <measure>Primary subscales from brief WISDM</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Dependence Measure</description>
  </other_outcome>
  <other_outcome>
    <measure>PATH Smoking Dependence Questions</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Dependence Measure (smoking and vaping)</description>
  </other_outcome>
  <other_outcome>
    <measure>Stages of Change</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Measure of intention to quit</description>
  </other_outcome>
  <other_outcome>
    <measure>Contemplation Ladder</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Measure of intention to quit</description>
  </other_outcome>
  <other_outcome>
    <measure>Quit attempts</measure>
    <time_frame>Baseline-Week 12</time_frame>
    <description>Measure of intention to quit</description>
  </other_outcome>
  <other_outcome>
    <measure>Post-intervention changes in tobacco use behavior</measure>
    <time_frame>30 Day Follow up</time_frame>
    <description>Measure of 30-day tobacco use post-intervention of study products</description>
  </other_outcome>
  <other_outcome>
    <measure>Qualitative Interview</measure>
    <time_frame>30 Day Follow up</time_frame>
    <description>Themes related to product use patterns, e-liquid flavor selection, non-compliance and general study feedback</description>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>NNC cigarette + moderate nicotine e-liquid + tobacco flavors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NNC cigarette + low nicotine e-liquid + tobacco flavors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with very low nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NNC cigarette + moderate nicotine e-liquid + variety flavors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NNC cigarette + low nicotine e-liquid + variety flavors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with very low or nicotine-free nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VLNC cigarette + moderate nicotine e-liquid + tobacco flavor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VLNC cigarette + low nicotine e-liquid +tobacco flavors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with very low or nicotine-free nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VLNC cigarette + moderate nicotine e-liquid + variety flavors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VLNC cigarette + low nicotine e-liquid + variety flavors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided with very low or nicotine-free nicotine content tobacco Spectrum Cigarettes along with very low nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NNC Spectrum Cigarette</intervention_name>
    <description>Participants are provided with normal nicotine content Spectrum Cigarette for 13 weeks.</description>
    <arm_group_label>NNC cigarette + low nicotine e-liquid + tobacco flavors</arm_group_label>
    <arm_group_label>NNC cigarette + low nicotine e-liquid + variety flavors</arm_group_label>
    <arm_group_label>NNC cigarette + moderate nicotine e-liquid + tobacco flavors</arm_group_label>
    <arm_group_label>NNC cigarette + moderate nicotine e-liquid + variety flavors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>VLNC Spectrum Cigarette</intervention_name>
    <description>Participants are provided with very low nicotine content Spectrum Cigarette for13 weeks</description>
    <arm_group_label>VLNC cigarette + low nicotine e-liquid + variety flavors</arm_group_label>
    <arm_group_label>VLNC cigarette + low nicotine e-liquid +tobacco flavors</arm_group_label>
    <arm_group_label>VLNC cigarette + moderate nicotine e-liquid + tobacco flavor</arm_group_label>
    <arm_group_label>VLNC cigarette + moderate nicotine e-liquid + variety flavors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Moderate nicotine level e-liquid</intervention_name>
    <description>Participants are provided with moderate nicotine level e-liquid for 13 weeks</description>
    <arm_group_label>NNC cigarette + moderate nicotine e-liquid + tobacco flavors</arm_group_label>
    <arm_group_label>NNC cigarette + moderate nicotine e-liquid + variety flavors</arm_group_label>
    <arm_group_label>VLNC cigarette + moderate nicotine e-liquid + tobacco flavor</arm_group_label>
    <arm_group_label>VLNC cigarette + moderate nicotine e-liquid + variety flavors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low nicotine level e-liquid</intervention_name>
    <description>Participants are provided with very low or nicotine-free nicotine level e-liquid for 13 weeks</description>
    <arm_group_label>NNC cigarette + low nicotine e-liquid + tobacco flavors</arm_group_label>
    <arm_group_label>NNC cigarette + low nicotine e-liquid + variety flavors</arm_group_label>
    <arm_group_label>VLNC cigarette + low nicotine e-liquid + variety flavors</arm_group_label>
    <arm_group_label>VLNC cigarette + low nicotine e-liquid +tobacco flavors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tobacco Flavors</intervention_name>
    <description>Participants can choose e-liquid flavors from a selection of tobacco flavors</description>
    <arm_group_label>NNC cigarette + low nicotine e-liquid + tobacco flavors</arm_group_label>
    <arm_group_label>NNC cigarette + moderate nicotine e-liquid + tobacco flavors</arm_group_label>
    <arm_group_label>VLNC cigarette + low nicotine e-liquid +tobacco flavors</arm_group_label>
    <arm_group_label>VLNC cigarette + moderate nicotine e-liquid + tobacco flavor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tobacco and non-tobacco e-liquid flavors</intervention_name>
    <description>Participants can choose e-liquid flavors from a selection of flavors that includes tobacco and non-tobacco choices</description>
    <arm_group_label>NNC cigarette + low nicotine e-liquid + variety flavors</arm_group_label>
    <arm_group_label>NNC cigarette + moderate nicotine e-liquid + variety flavors</arm_group_label>
    <arm_group_label>VLNC cigarette + low nicotine e-liquid + variety flavors</arm_group_label>
    <arm_group_label>VLNC cigarette + moderate nicotine e-liquid + variety flavors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Smokers who have tried vaping multiple times.

          -  Generally good health.

        Exclusion Criteria:

          -  If female, currently pregnant, trying to become pregnant or breastfeeding.

          -  Planning to quit smoking.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Donny, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest Biotech Place</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Agaku IT, King BA, Husten CG, Bunnell R, Ambrose BK, Hu SS, Holder-Hayes E, Day HR; Centers for Disease Control and Prevention (CDC). Tobacco product use among adults--United States, 2012-2013. MMWR Morb Mortal Wkly Rep. 2014 Jun 27;63(25):542-7. Erratum in: MMWR Morb Mortal Wkly Rep. 2014 Jul 4;63(26):576.</citation>
    <PMID>24964880</PMID>
  </reference>
  <reference>
    <citation>Arrazola RA, Singh T, Corey CG, Husten CG, Neff LJ, Apelberg BJ, Bunnell RE, Choiniere CJ, King BA, Cox S, McAfee T, Caraballo RS; Centers for Disease Control and Prevention (CDC). Tobacco use among middle and high school students - United States, 2011-2014. MMWR Morb Mortal Wkly Rep. 2015 Apr 17;64(14):381-5.</citation>
    <PMID>25879896</PMID>
  </reference>
  <reference>
    <citation>Baker H. E-cigarettes and subsequent tobacco use in adolescence. Lancet Oncol. 2015 Oct;16(13):e481. doi: 10.1016/S1470-2045(15)00272-7. Epub 2015 Aug 28.</citation>
    <PMID>26321209</PMID>
  </reference>
  <reference>
    <citation>Bandiera FC, Ross KC, Taghavi S, Delucchi K, Tyndale RF, Benowitz NL. Nicotine Dependence, Nicotine Metabolism, and the Extent of Compensation in Response to Reduced Nicotine Content Cigarettes. Nicotine Tob Res. 2015 Sep;17(9):1167-72. doi: 10.1093/ntr/ntu337. Epub 2015 Jan 2.</citation>
    <PMID>25555385</PMID>
  </reference>
  <reference>
    <citation>BECK AT, WARD CH, MENDELSON M, MOCK J, ERBAUGH J. An inventory for measuring depression. Arch Gen Psychiatry. 1961 Jun;4:561-71.</citation>
    <PMID>13688369</PMID>
  </reference>
  <reference>
    <citation>Biener L, Abrams DB. The Contemplation Ladder: validation of a measure of readiness to consider smoking cessation. Health Psychol. 1991;10(5):360-5.</citation>
    <PMID>1935872</PMID>
  </reference>
  <reference>
    <citation>Benowitz NL, Pomerleau OF, Pomerleau CS, Jacob P 3rd. Nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine Tob Res. 2003 Oct;5(5):621-4.</citation>
    <PMID>14577978</PMID>
  </reference>
  <reference>
    <citation>Benowitz NL, Henningfield JE. Establishing a nicotine threshold for addiction. The implications for tobacco regulation. N Engl J Med. 1994 Jul 14;331(2):123-5.</citation>
    <PMID>7818638</PMID>
  </reference>
  <reference>
    <citation>Benowitz NL, Dains KM, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P 3rd. Progressive commercial cigarette yield reduction: biochemical exposure and behavioral assessment. Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):876-83. doi: 10.1158/1055-9965.EPI-08-0731. Epub 2009 Mar 3.</citation>
    <PMID>19258480</PMID>
  </reference>
  <reference>
    <citation>Benowitz NL, Dains KM, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P 3rd. Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes. Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):761-9. doi: 10.1158/1055-9965.EPI-11-0644. Epub 2012 Feb 21.</citation>
    <PMID>22354905</PMID>
  </reference>
  <reference>
    <citation>Benowitz NL, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P 3rd. Nicotine and carcinogen exposure with smoking of progressively reduced nicotine content cigarette. Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2479-85.</citation>
    <PMID>18006940</PMID>
  </reference>
  <reference>
    <citation>Benowitz NL, Nardone N, Dains KM, Hall SM, Stewart S, Dempsey D, Jacob P 3rd. Effect of reducing the nicotine content of cigarettes on cigarette smoking behavior and tobacco smoke toxicant exposure: 2-year follow up. Addiction. 2015 Oct;110(10):1667-75. doi: 10.1111/add.12978. Epub 2015 Jul 21.</citation>
    <PMID>26198394</PMID>
  </reference>
  <reference>
    <citation>Blank MD, Disharoon S, Eissenberg T. Comparison of methods for measurement of smoking behavior: mouthpiece-based computerized devices versus direct observation. Nicotine Tob Res. 2009 Jul;11(7):896-903. doi: 10.1093/ntr/ntp083. Epub 2009 Jun 11.</citation>
    <PMID>19525207</PMID>
  </reference>
  <reference>
    <citation>Brauer LH, Hatsukami D, Hanson K, Shiffman S. Smoking topography in tobacco chippers and dependent smokers. Addict Behav. 1996 Mar-Apr;21(2):233-8.</citation>
    <PMID>8730526</PMID>
  </reference>
  <reference>
    <citation>Buchhalter AR, Acosta MC, Evans SE, Breland AB, Eissenberg T. Tobacco abstinence symptom suppression: the role played by the smoking-related stimuli that are delivered by denicotinized cigarettes. Addiction. 2005 Apr;100(4):550-9.</citation>
    <PMID>15784070</PMID>
  </reference>
  <reference>
    <citation>Butschky MF, Bailey D, Henningfield JE, Pickworth WB. Smoking without nicotine delivery decreases withdrawal in 12-hour abstinent smokers. Pharmacol Biochem Behav. 1995 Jan;50(1):91-6.</citation>
    <PMID>7700960</PMID>
  </reference>
  <reference>
    <citation>Caggiula AR, Donny EC, White AR, Chaudhri N, Booth S, Gharib MA, Hoffman A, Perkins KA, Sved AF. Cue dependency of nicotine self-administration and smoking. Pharmacol Biochem Behav. 2001 Dec;70(4):515-30. Review.</citation>
    <PMID>11796151</PMID>
  </reference>
  <reference>
    <citation>Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults--United States, 2000. MMWR Morb Mortal Wkly Rep. 2002 Jul 26;51(29):642-5.</citation>
    <PMID>12186222</PMID>
  </reference>
  <reference>
    <citation>Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983 Dec;24(4):385-96.</citation>
    <PMID>6668417</PMID>
  </reference>
  <reference>
    <citation>Congress (2009). Family Smoking Prevention and Tobacco Control Act. (H.R. 1256). U. S. Congress. Washington, D.C., U.S. Government Printing Office.</citation>
  </reference>
  <reference>
    <citation>Conklin CA, Tiffany ST. Applying extinction research and theory to cue-exposure addiction treatments. Addiction. 2002 Feb;97(2):155-67.</citation>
    <PMID>11860387</PMID>
  </reference>
  <reference>
    <citation>Cox LS, Tiffany ST, Christen AG. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob Res. 2001 Feb;3(1):7-16.</citation>
    <PMID>11260806</PMID>
  </reference>
  <reference>
    <citation>Dawkins L, Turner J, Crowe E. Nicotine derived from the electronic cigarette improves time-based prospective memory in abstinent smokers. Psychopharmacology (Berl). 2013 Jun;227(3):377-84. doi: 10.1007/s00213-013-2983-2. Epub 2013 Jan 24.</citation>
    <PMID>23344557</PMID>
  </reference>
  <reference>
    <citation>Dawkins L, Turner J, Hasna S, Soar K. The electronic-cigarette: effects on desire to smoke, withdrawal symptoms and cognition. Addict Behav. 2012 Aug;37(8):970-3. doi: 10.1016/j.addbeh.2012.03.004. Epub 2012 Mar 10.</citation>
    <PMID>22503574</PMID>
  </reference>
  <reference>
    <citation>Food and Drug Administration, HHS. Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products. Final rule. Fed Regist. 2016 May 10;81(90):28973-9106.</citation>
    <PMID>27192730</PMID>
  </reference>
  <reference>
    <citation>Dempsey D, Tutka P, Jacob P 3rd, Allen F, Schoedel K, Tyndale RF, Benowitz NL. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther. 2004 Jul;76(1):64-72.</citation>
    <PMID>15229465</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 22, 2017</study_first_submitted>
  <study_first_submitted_qc>June 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>smoking</keyword>
  <keyword>vaping</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be available to other researchers, please contact the principal investigator for instructions.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

